Health
Novavax Covid vaccine highly effective, but not against S.Africa variant – Yahoo News Australia
US biotech firm Novavax said Thursday its two-shot Covid-19 vaccine showed an overall efficacy of 89.3 percent in a major Phase 3 clinical trial in Britain, …
US biotech firm Novavax said Thursday its two-shot Covid-19 vaccine showed an overall efficacy of 89.3 percent in a major Phase 3 clinical trial in Britain, and remained highly effective against a variant first identified there.
But the positive news was partly offset by other results that showed it offered significantly less protection against a highly transmissible variant of the coronavirus first identified in South Africa, which is spreading rapidly around the world.
Novavax said it began working…
-
Business21 hours agoMacquarie tips 14% upside for this ASX tech stock
-
Noosa News17 hours agoWilliam Robinson dies aged 89
-
Business21 hours agoWhat to do with these 3 ASX 200 retail shares after strong price runs: experts
-
General17 hours agoCalls for corruption probe into completion of mayor’s Surfers Paradise Bowls Club site purchase